Lucia Alcober-Boquet, Nico Kraus, Lisa Sophie Huber, Rajkumar Vutukuri, Dominik Christian Fuhrmann, Claudia Stross, Liliana Schaefer, Klaus Scholich, Stefan Zeuzem, Albrecht Piiper, Marcel H Schulz, Jonel Trebicka, Christoph Welsch, Cristina Ortiz
17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13), a lipid droplet-associated enzyme, is primarily expressed in the liver and plays an important role in lipid metabolism. Targeted inhibition of enzymatic function is a potential therapeutic strategy for treating steatotic liver disease (SLD). The present study is aimed at investigating the effects of the first selective HSD17B13 inhibitor, BI-3231, in a model of hepatocellular lipotoxicity using human cell lines and primary mouse hepatocytes, in vitro . Lipotoxicity was induced with palmitic acid in HepG2 cells and freshly isolated mouse hepatocytes and the cells were co-incubated with BI-3231 to assess the protective effects...
January 15, 2024: American Journal of Physiology. Cell Physiology